Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15762585 | 0.87 | GAA (0.36) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14800050 | 0.85 | MEN1 (0.38) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14800049 | 0.85 | MEN1 (0.38) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799870 | 0.81 | MEN1 (0.35) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799204 | 0.81 | GAA (0.36) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799203 | 0.81 | GAA (0.36) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799871 | 0.81 | MEN1 (0.35) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799652 | 0.78 | MEN1 (0.43) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| SCHEMBL14799651 | 0.78 | MEN1 (0.43) | MEN1KMT2AMAPK1L3MBTL1GAA | |
| Propane SCHEMBL28340961 | 0.76 | MEN1 (0.31) | MEN1KMT2AMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193150-B1 | SYNTHESIS OF A LIQUID POLYMER AND A FUNCTIONALIZED POLYMER | BRIDGESTONE CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-7981990-B2 | Synthesis of a liquid polymer and a functionalized polymer | BRIDGESTONE CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| WO-2009032154-A2 | SYNTHESIS OF A LIQUID POLYMER AND A FUNCTIONALIZED POLYMER | BRIDGESTONE CORPORATION (JP) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062451-A1 | SYNTHESIS OF A LIQUID POLYMER AND A FUNCTIONALIZED POLYMER | BRIDGESTONE CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062451-A1 | SYNTHESIS OF A LIQUID POLYMER AND A FUNCTIONALIZED POLYMER | FGB, FIP1L1, PUF60 | MEN1 1390/4885KMT2A 783/4885MAPK1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.